- Home
- FVCB vs ACRS Comparison
FVCB vs ACRS Comparison
Compare FVCB & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FVCB
- ACRS
- Stock Information
- Founded
- FVCB 2007
- ACRS 2012
- Country
- FVCB United States
- ACRS United States
- Employees
- FVCB N/A
- ACRS N/A
- Industry
- FVCB Major Banks
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- FVCB Finance
- ACRS Health Care
- Exchange
- FVCB Nasdaq
- ACRS Nasdaq
- Market Cap
- FVCB 204.0M
- ACRS 165.7M
- IPO Year
- FVCB N/A
- ACRS 2015
- Fundamental
- Price
- FVCB $11.80
- ACRS $1.42
- Analyst Decision
- FVCB
- ACRS Strong Buy
- Analyst Count
- FVCB 0
- ACRS 8
- Target Price
- FVCB N/A
- ACRS $9.71
- AVG Volume (30 Days)
- FVCB 43.2K
- ACRS 1.3M
- Earning Date
- FVCB 07-24-2025
- ACRS 08-06-2025
- Dividend Yield
- FVCB N/A
- ACRS N/A
- EPS Growth
- FVCB 311.46
- ACRS N/A
- EPS
- FVCB 1.03
- ACRS N/A
- Revenue
- FVCB $60,453,000.00
- ACRS $17,777,000.00
- Revenue This Year
- FVCB $8.48
- ACRS N/A
- Revenue Next Year
- FVCB $7.88
- ACRS $11.77
- P/E Ratio
- FVCB $11.46
- ACRS N/A
- Revenue Growth
- FVCB 34.53
- ACRS N/A
- 52 Week Low
- FVCB $9.49
- ACRS $1.05
- 52 Week High
- FVCB $14.50
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- FVCB 56.68
- ACRS 57.34
- Support Level
- FVCB $11.69
- ACRS $1.34
- Resistance Level
- FVCB $12.03
- ACRS $1.66
- Average True Range (ATR)
- FVCB 0.33
- ACRS 0.09
- MACD
- FVCB 0.03
- ACRS 0.01
- Stochastic Oscillator
- FVCB 67.39
- ACRS 69.55
About FVCB FVCBankcorp Inc.
FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, FVCbank which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.